SLC5A2 and type 2 diabetes mellitus: Therefore, the use of SGLT-2 inhibitors is more applicable to patients with T2DM at high risk of cardiac metabolic disease, rather than restricting its use for weight loss and hypoglycemic effect in patients with T2DM.